Want to see TWST full AI Analyst Report?
TWST Stock Chart & Stats
$151.42
-$2.17(-2.35%)
At close: 4:00 PM EDT
$151.42
-$2.17(-2.35%)
Day’s Range― - ―
52-Week Range$23.30 - $219.71
Previous CloseN/A
Volume1.05M
Average Volume (3M)2.78M
Market Cap
$9.20B
Enterprise Value$6.35B
Total Cash (Recent Filing)$166.84M
Total Debt (Recent Filing)$93.59M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 13, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding65,832,420
10 Day Avg. Volume3,825,346
30 Day Avg. Volume2,783,295
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue14.70
Enterprise Value/Gross Profit28.29
Enterprise Value/Ebitda-58.88
Forecast
1Y Price Target
$158.10Price Target Upside4.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.31
Revenue Forecast (FY)$548.60M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin GrowthSustained revenue expansion alongside improving gross margin indicates stronger customer adoption and better economics in the synthetic biology platform. Continued growth creates operating leverage potential, while higher gross profit can support investment in products, capacity, and commercial execution over the next several quarters.
Manufacturing EfficiencyThe reported efficiency gains provide a durable competitive advantage by improving throughput, reducing production costs, and shortening customer delivery times. These improvements can support scalable growth and help sustain gross-margin expansion as order volumes increase across DNA synthesis and related workflows.
AI-Enabled Protein Design PositioningThe Anthropic engagement structurally reinforces Twist’s role between computational protein design and laboratory validation. If repeat customers and AI-driven discovery programs continue expanding, Twist may gain additional demand for high-throughput manufacturing and testing services across emerging biotechnology workflows.
Bears Say
Persistent Cash BurnNegative operating and free cash flow means the business has not yet funded its operations internally despite revenue growth. Continued cash consumption can constrain investment flexibility and require additional financing until the company converts improving margins and scale into sustainably positive cash generation.
Unresolved Operating LossesTwist remains materially unprofitable, so revenue growth has not yet translated into dependable operating leverage. The path to adjusted EBITDA breakeven depends on execution and expense control, leaving earnings vulnerable if growth slows or planned investments keep operating costs elevated.
Revenue Conversion And Competitive PressureUncertain timing between orders and recognized revenue can make business performance less predictable, particularly for large AI-driven projects. Competitive actions and discounting could also pressure sequencing and protein-business mix or average selling prices, limiting the durability of growth and margin gains.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was $23.30 and its highest was $219.71 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is $9.20B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is Nov 13, 2026 which is in 23 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on Aug 03, 2026. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.506 by -$0.054.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.39.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 65,832,420 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.506. Following the earnings report the stock price went up 10.388%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$158.10 (4.41% Upside)
$158.10 (4.41% Upside)
Blogger Sentiment
Neutral
TWST Sentiment 65%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $275.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
396.34%
12-Months-Change
Fundamentals
Return on Equity
-29.89%
Trailing 12-Months
Asset Growth
4.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
TWST Company Deck
TWST Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$158.10
▲(4.41% Upside)
Technical Analysis
Adaptive Biotechnologies
―
10x Genomics
―
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
AbSci
―
Ownership Overview
2.19% Insiders
25.77% Mutual Funds
0.09% Other Institutional Investors
45.38% Public Companies and
Individual Investors